We found that MHC class II molecules DP alpha1 (HLA-DPA1) and DP beta 1 (HLA-DPB1) were downregulated in patients with recurrence, suggesting suppression of immunity to cancer. This evidence concerns the gene HLA-DPA1 and cancer.